Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 17/20 | 0.54 |
| ▸ | BRD2 | P25440 | 1/20 | 0.49 |
| ▸ | EP300 | Q09472 | 1/20 | 0.49 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.49 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.49 |
| ▸ | FASN | P49327 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10371 | 1.00 | BRD4 (0.54) | BRD4BRD2EP300BRD3BRDT | |
| SCHEMBL22220810 | 1.00 | BRD4 (0.54) | BRD4BRD2EP300BRD3BRDT | |
| SCHEMBL10650 | 0.93 | P2RX3 (0.54) | BRD4BRD2EP300BRD3BRDT | |
| SCHEMBL22220872 | 0.93 | P2RX3 (0.54) | BRD4BRD2EP300BRD3BRDT | |
| SCHEMBL10649 | 0.93 | P2RX3 (0.54) | BRD4BRD2EP300BRD3BRDT | |
| SCHEMBL10624 | 0.92 | BRD4 (0.50) | BRD4BRD2EP300BRD3BRDT | |
| SCHEMBL22220868 | 0.92 | BRD4 (0.50) | BRD4BRD2EP300BRD3BRDT | |
| SCHEMBL10623 | 0.92 | BRD4 (0.50) | BRD4BRD2EP300BRD3BRDT | |
| SCHEMBL22220804 | 0.92 | FASN (0.50) | BRD4BRD2EP300BRD3BRDT | |
| SCHEMBL10741 | 0.92 | FASN (0.50) | BRD4BRD2EP300BRD3BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020150423-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-16 | — | — | US | disclosed |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-16 | — | — | US | disclosed |
| EP-2493310-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline LLC (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120208827-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| US-20120208827-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| US-20120208827-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| WO-2011056635-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011056635-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208827-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | BRD4 277/4885BRD2 520/4885EP300 1139/4885 |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | BRD4 2526/4885BRD2 3368/4885EP300 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.